Swiss Helvetia Fund
1270 Avenue of the Americas, Suite 400, New York, NY, 10020, United States
Overview
Swiss Helvetia Fund is a non-diversified, closed-end investment company whose objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The Fund also may acquire and hold equity and equity-linked securities of non-Swiss companies in limited instances.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Financial Services
Investment portfolio
- Synosia Therapeutics
Participated · Series C · Oct 2010
Synosia Therapeutics is a Basel, Switzerland–based biotherapeutics company developing treatments for neurological and psychiatric disorders. The company has six clinical-stage compounds in its pipeline targeting conditions including Parkinson's and Alzheimer's disease. Its lead compounds, SYN-115 and SYN-118, are in development to treat Parkinson's disease. Synosia announced a strategic collaboration with UCB that covers those lead compounds. The company raised $30M in a Series C financing as part of the collaboration. UCB executives Greg Duncan and Ismail Kola will join Synosia's board of directors under the agreement.
Team
No current team members are available.